AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Other: Placebo

First Posted Date: 2017-11-20

Last Posted Date: 2021-11-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 1061

Registration Number: NCT03347279

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

A Phase IV Study in Drug-Naive Patients With T2DM in China

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Dapagliflozin
Drug: Acarbose

First Posted Date: 2017-11-17

Last Posted Date: 2021-12-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 304

Registration Number: NCT03344341

Locations: 🇨🇳
Research Site, Yinchuan, China

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Phase 2

Completed

Conditions: Hyperkalemia

Interventions: Drug: Sodium Zirconium Cyclosilicate(ZS)
Drug: Placebo
Drug: Insulin
Drug: Glucose

First Posted Date: 2017-11-09

Last Posted Date: 2020-01-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT03337477

Locations: 🇷🇺
Research Site, Yekaterinburg, Russian Federation

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.

Phase 4

Completed

Conditions: Skeletal Muscle Insulin Sensitivity
Diabetes Mellitus, Type 2

Interventions: Drug: Dapagliflozin

First Posted Date: 2017-11-09

Last Posted Date: 2021-01-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 26

Registration Number: NCT03338855

Locations: 🇳🇱
Research Site, Maastricht, Netherlands

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: CYP1A2 (caffeine)
Drug: CYP2C19 (omeprazole)
Drug: CYP3A (midazolam)
Drug: Kytril (granisetron)
Drug: Wee-1 kinase inhibitor AZD1775

First Posted Date: 2017-11-07

Last Posted Date: 2019-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 33

Registration Number: NCT03333824

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: AZD6738 (ceralasertib)
Drug: AZD6738 (ceralasertib) 7 days monotherapy
Drug: AZD6738 (ceralasertib) (240 mg or 160 mg)
Drug: trastuzumab deruxtecan
Drug: Olaparib
Drug: AZD9150
Drug: Vistusertib
Drug: AZD6738
Drug: Oleclumab
Drug: cediranib

First Posted Date: 2017-11-07

Last Posted Date: 2025-04-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 527

Registration Number: NCT03334617

Locations: 🇪🇸
Research Site, Sevilla, Spain

A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Aclidinium bromide/formoterol
Drug: Aclidinium bromide
Drug: Other COPD medication

First Posted Date: 2017-11-06

Last Posted Date: 2018-02-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 22155

Registration Number: NCT03333018

Locations: 🇬🇧
Clinical Practice Research Datalink, London, United Kingdom
🇩🇰
National Health Database Denmark, Southern Denmark University, Odense, Denmark
🇩🇪
German Pharmacoepidemiological Research Database, Bremen, Germany

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2

Active, not recruiting

Conditions: Metastatic Triple Negative Breast Cancer

Interventions: Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

First Posted Date: 2017-11-06

Last Posted Date: 2025-06-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 273

Registration Number: NCT03330847

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: AZD5718
Drug: Placebo

First Posted Date: 2017-10-23

Last Posted Date: 2021-06-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 129

Registration Number: NCT03317002

Locations: 🇸🇪
Research Site, Uppsala, Sweden

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Phase 2

Completed

Conditions: Asymptomatic Hyperuricemia

Interventions: Drug: Verinurad
Drug: Febuxostat
Drug: Dapagliflozin
Other: Dapagliflozin matched placebo

First Posted Date: 2017-10-20

Last Posted Date: 2019-08-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT03316131

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Home Terms & Conditions Privacy Policy